Qiagen NV (QGEN) Given Average Rating of “Hold” by Brokerages
Qiagen NV (NASDAQ:QGEN) has been given an average rating of “Hold” by the fifteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $33.36.
A number of research analysts recently issued reports on the company. TheStreet raised Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Zacks Investment Research lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Wednesday, November 8th. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research report on Tuesday, December 12th. Finally, BidaskClub upgraded Qiagen from a “sell” rating to a “hold” rating in a research report on Wednesday.
Several institutional investors have recently made changes to their positions in QGEN. Dimensional Fund Advisors LP lifted its holdings in shares of Qiagen by 0.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 73,215 shares of the company’s stock valued at $2,121,000 after buying an additional 306 shares during the last quarter. Public Employees Retirement Association of Colorado raised its stake in shares of Qiagen by 3.5% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after acquiring an additional 246 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Qiagen by 3.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 188,102 shares of the company’s stock valued at $6,308,000 after acquiring an additional 6,557 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Qiagen by 4.4% in the 2nd quarter. Rhumbline Advisers now owns 216,769 shares of the company’s stock valued at $7,268,000 after acquiring an additional 9,208 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its stake in shares of Qiagen by 9.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 23,444 shares of the company’s stock valued at $786,000 after acquiring an additional 2,002 shares in the last quarter. Institutional investors and hedge funds own 62.24% of the company’s stock.
Qiagen (NASDAQ:QGEN) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting analysts’ consensus estimates of $0.32. The company had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $0.29 earnings per share. sell-side analysts predict that Qiagen will post 1.25 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Qiagen NV (QGEN) Given Average Rating of “Hold” by Brokerages” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/21/qiagen-nv-qgen-given-average-rating-of-hold-by-brokerages.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.